JPMorgan Chase & Co. Lowers Medtronic (NYSE:MDT) Price Target to $96.00

Medtronic (NYSE:MDT - Get Free Report) had its price objective dropped by equities research analysts at JPMorgan Chase & Co. from $99.00 to $96.00 in a research note issued to investors on Friday. The brokerage currently has a "neutral" rating on the medical technology company's stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 9.84% from the stock's previous close.

A number of other equities analysts have also recently commented on the stock. Daiwa America raised shares of Medtronic to a "strong-buy" rating in a research note on Friday, August 23rd. Truist Financial raised their price objective on Medtronic from $90.00 to $93.00 and gave the company a "hold" rating in a research report on Monday, October 14th. Robert W. Baird lifted their price target on Medtronic from $82.00 to $90.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 21st. Stifel Nicolaus raised their price target on shares of Medtronic from $85.00 to $87.00 and gave the company a "hold" rating in a report on Wednesday, August 21st. Finally, Piper Sandler upped their target price on shares of Medtronic from $85.00 to $90.00 and gave the company a "neutral" rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of "Hold" and an average target price of $95.80.

Medtronic Stock Up 1.6 %

NYSE:MDT traded up $1.40 during trading hours on Friday, hitting $87.40. 4,724,437 shares of the company traded hands, compared to its average volume of 6,210,865. The firm's 50-day simple moving average is $89.52 and its 200-day simple moving average is $84.67. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. The company has a market cap of $112.09 billion, a PE ratio of 29.53, a PEG ratio of 2.51 and a beta of 0.84. Medtronic has a one year low of $74.20 and a one year high of $92.68.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.03. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The business had revenue of $7.97 billion during the quarter, compared to analyst estimates of $7.90 billion. During the same period in the prior year, the company earned $1.20 earnings per share. Medtronic's revenue was up 3.4% compared to the same quarter last year. Equities analysts predict that Medtronic will post 5.44 earnings per share for the current year.

Institutional Trading of Medtronic

A number of institutional investors have recently bought and sold shares of MDT. Nwam LLC raised its holdings in Medtronic by 3.2% in the first quarter. Nwam LLC now owns 4,492 shares of the medical technology company's stock worth $371,000 after purchasing an additional 141 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its stake in shares of Medtronic by 3.4% during the first quarter. Pinnacle Wealth Planning Services Inc. now owns 4,118 shares of the medical technology company's stock worth $359,000 after purchasing an additional 137 shares in the last quarter. Nicolet Advisory Services LLC acquired a new position in Medtronic in the 1st quarter valued at $247,000. TIAA Trust National Association boosted its holdings in shares of Medtronic by 16.1% during the 1st quarter. TIAA Trust National Association now owns 8,083 shares of the medical technology company's stock worth $704,000 after purchasing an additional 1,119 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in shares of Medtronic in the 1st quarter worth $1,616,000. 82.06% of the stock is currently owned by institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.